Prostate-specific membrane antigen radioligand therapy of prostate cancer

Mohsen Beheshti; Alexander Heinzel; Dirk von Mallek; Christian Filss; Felix M. Mottaghy

doi:10.23736/S1824-4785.19.03155-8

Prostate-specific membrane antigen radioligand therapy of prostate cancer

Mohsen Beheshti^*
, Alexander Heinzel
, Dirk von Mallek
, Christian Filss
, Felix M. Mottaghy

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

Defining an optimal therapeutic approach in metastatic castration-resistance prostate cancer (mCRPC) patients in advanced stages is still chal-lengina in routine clinical practice. Prostate-specific membrane antigen (PSMA) targeted radionuclide therapy with beta- or alpha-emitters such as 177-Lutethium (Lu-177) or 225-Actinium ((225)A) has been a main focus at multiple academic research centers in the last few years. This review article provides an overview of PSMA characteristics. clinical performance, safety and toxicity of PSMA targeted beta- or alpha-radiation therapy.

Original language	English
Pages (from-to)	29-36
Number of pages	8
Journal	Quarterly Journal of Nuclear Medicine and Molecular Imaging
Volume	63
Issue number	1
DOIs	https://doi.org/10.23736/S1824-4785.19.03155-8
Publication status	Published - Mar 2019

Keywords

Prostatic neoplasms
Lu-177-PSMA-617
Radiotherapy
TARGETED ALPHA-THERAPY
RADIATION-DOSIMETRY
PSMA LIGANDS
PRECLINICAL EVALUATION
RADIONUCLIDE THERAPY
PHASE-II
BIODISTRIBUTION
INHIBITORS
PET
ANTIBODY

Access to Document

10.23736/S1824-4785.19.03155-8

Cite this

@article{1834fc13ef944ec39e28a6e02fd4d131,

title = "Prostate-specific membrane antigen radioligand therapy of prostate cancer",

abstract = "Defining an optimal therapeutic approach in metastatic castration-resistance prostate cancer (mCRPC) patients in advanced stages is still chal-lengina in routine clinical practice. Prostate-specific membrane antigen (PSMA) targeted radionuclide therapy with beta- or alpha-emitters such as 177-Lutethium (Lu-177) or 225-Actinium ((225)A) has been a main focus at multiple academic research centers in the last few years. This review article provides an overview of PSMA characteristics. clinical performance, safety and toxicity of PSMA targeted beta- or alpha-radiation therapy.",

keywords = "Prostatic neoplasms, Lu-177-PSMA-617, Radiotherapy, TARGETED ALPHA-THERAPY, RADIATION-DOSIMETRY, PSMA LIGANDS, PRECLINICAL EVALUATION, RADIONUCLIDE THERAPY, PHASE-II, BIODISTRIBUTION, INHIBITORS, PET, ANTIBODY",

author = "Mohsen Beheshti and Alexander Heinzel and \{von Mallek\}, Dirk and Christian Filss and Mottaghy, \{Felix M.\}",

note = "Publisher Copyright: {\textcopyright} 2019 EDIZIONI MINERVA MEDICA.",

year = "2019",

month = mar,

doi = "10.23736/S1824-4785.19.03155-8",

language = "English",

volume = "63",

pages = "29--36",

journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",

issn = "1824-4785",

publisher = "Edizioni Minerva Medica",

number = "1",

}

TY - JOUR

T1 - Prostate-specific membrane antigen radioligand therapy of prostate cancer

AU - Beheshti, Mohsen

AU - Heinzel, Alexander

AU - von Mallek, Dirk

AU - Filss, Christian

AU - Mottaghy, Felix M.

PY - 2019/3

Y1 - 2019/3

N2 - Defining an optimal therapeutic approach in metastatic castration-resistance prostate cancer (mCRPC) patients in advanced stages is still chal-lengina in routine clinical practice. Prostate-specific membrane antigen (PSMA) targeted radionuclide therapy with beta- or alpha-emitters such as 177-Lutethium (Lu-177) or 225-Actinium ((225)A) has been a main focus at multiple academic research centers in the last few years. This review article provides an overview of PSMA characteristics. clinical performance, safety and toxicity of PSMA targeted beta- or alpha-radiation therapy.

AB - Defining an optimal therapeutic approach in metastatic castration-resistance prostate cancer (mCRPC) patients in advanced stages is still chal-lengina in routine clinical practice. Prostate-specific membrane antigen (PSMA) targeted radionuclide therapy with beta- or alpha-emitters such as 177-Lutethium (Lu-177) or 225-Actinium ((225)A) has been a main focus at multiple academic research centers in the last few years. This review article provides an overview of PSMA characteristics. clinical performance, safety and toxicity of PSMA targeted beta- or alpha-radiation therapy.

KW - Prostatic neoplasms

KW - Lu-177-PSMA-617

KW - Radiotherapy

KW - TARGETED ALPHA-THERAPY

KW - RADIATION-DOSIMETRY

KW - PSMA LIGANDS

KW - PRECLINICAL EVALUATION

KW - RADIONUCLIDE THERAPY

KW - PHASE-II

KW - BIODISTRIBUTION

KW - INHIBITORS

KW - PET

KW - ANTIBODY

U2 - 10.23736/S1824-4785.19.03155-8

DO - 10.23736/S1824-4785.19.03155-8

M3 - (Systematic) Review article

C2 - 30644306

SN - 1824-4785

VL - 63

SP - 29

EP - 36

JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

IS - 1

ER -

Prostate-specific membrane antigen radioligand therapy of prostate cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this